EIM
IOVA icon

Essex Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Essex Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-32,593
Closed -$902K – 423
2019
Q4 		$902K Buy
32,593
+361
+1% +$8.21K 0.11% 246
2019
Q3 		$587K Buy
+32,232
New +$713K 0.08% 277

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Essex Investment Management's IOVA Position: Q1 2020 in Review

Essex Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2020, closing a stake of 32,593 shares — an estimated $902K sold.

Essex Investment Management first reported a position in IOVA in Q3 2019 and held it in 2 quarters. The position peaked at $902K in Q4 2019. 219 funds tracked by Wall St. Rank hold IOVA as of Q1 2020.

  • Essex Investment Management reported no remaining Iovance Biotherapeutics position as of Q1 2020 after selling out during the quarter.
  • Essex Investment Management sold 32,593 Iovance Biotherapeutics shares in Q1 2020, an estimated $902K.
  • Essex Investment Management first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 2 quarters.
  • Essex Investment Management's Iovance Biotherapeutics position peaked at $902K in Q4 2019.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2020.

Based on Essex Investment Management's 13F filing for Q1 2020, filed 4 May 2020.